1. Scrip
  2. >>Business
  3. >>Start-Ups & SMEs

MatriSys Focuses On ‘Good Microbe’ Approach To Dermatology, Maybe Skin Cancer Too

 
• By Joseph Haas

Emerging Company Profile: Calling itself the most advanced microbiome company focused on skin diseases, MatriSys has advanced a proprietary microbe to Phase IIa for atopic dermatitis. The biotech also is eyeing UV-induced cancer, rosacea, acne, psoriasis and bacterial skin infections.

Emerging Company Profile Regular column feature image Version 2

Often the first thing MatriSys Bioscience Inc.’s team needs to explain to potential investors is that microbiome therapy isn’t focused solely on gastrointestinal disorders, although that’s an easier task since the firm unveiled interim Phase IIa data for lead candidate MSB-01 in atopic dermatitis in February.

While MSB-01 – a topical preparation of a proprietary bacterial strain of the microbe Staphylococcus hominis A9 – completes the NIH-funded Phase IIa study, San Diego-area MatriSys is working to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Start-Ups & SMEs

More from Business

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal

 
• By Mandy Jackson

Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.